Cover Image

The role of baseline 2‐[ 18 F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Domenico Albano, Anna Calabrò, Francesco Dondi, Samuele Bagnasco, Alessandra Tucci, Francesco Bertagna
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Hematological Oncology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2‐[ 18 F]FDG PET/CT in Advanced Mantle Cell Lymphoma
by: Domenico Albano, et al.
Published: (2024)

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement
by: Elisabetta M. Abenavoli, et al.
Published: (2024)

514 | CAN BASELINE 18F‐FDG PET/CT PREDICT THE PROGNOSIS OF PRIMARY CNS LYMPHOMA?
by: H. Zhu, et al.
Published: (2025)

508 | BAYESIAN PENALIZED LIKELIHOOD RECONSTRUCTION ALGORITHM RESULTS IN SIMILAR PROGNOSTIC MARKERS ON FDG PET/CT IN DLBCL
by: H. L. Huang, et al.
Published: (2025)

513 | PROGNOSTIC PREDICTIVE VALUE OF BASELINE 18F‐FDG PET/CT METABOLIC PARAMETERS IN HODGKIN’S LYMPHOMA
by: H. Zhang, et al.
Published: (2025)

13 | PROGNOSTIC VALUE OF THE COMBINATION OF RADIOMICS PARAMETERS MEASURED ON BASELINE FDG PET/CT IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA
by: P. Decazes, et al.
Published: (2025)

512 | PROGNOSTIC VALUE OF BASELINE METABOLIC BIOMARKERS ASSESSED BY F18‐FDG PET/CT IN DIFFUSE LARGE B‐CELL LYMPHOMA
by: B. Chen, et al.
Published: (2025)

LBA4 | DEEP LEARNING‐BASED IMAGE ANALYSIS OF PRETREATMENT FDG‐PET/CT PREDICTS CAR T‐CELL TREATMENT OUTCOME AT 12 MONTHS
by: S. J. Schuster, et al.
Published: (2025)

Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
by: Kaitlin Annunzio, et al.
Published: (2024)

373 | PROGNOSTIC VALUE OF 18F‐FDG PET/CT VOLUMETRIC PARAMETERS IN CHILDHOOD, ADOLESCENT, AND YOUNG ADULT HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW FROM THE SEARCH GROUP
by: C. Gowdy, et al.
Published: (2025)

410 | EVALUATION OF AN ARTIFICIAL INTELLIGENCE METHOD FOR LESION SEGMENTATION OF BASELINE FDG PET STUDIES OF DLBCL PATIENTS
by: M. C. Ferrandez, et al.
Published: (2025)

Characterizing second line and beyond therapies for primary central nervous system lymphomas
by: Brian Primeaux, et al.
Published: (2024)

409 | EARLY IDENTIFICATION OF CAR T‐CELL THERAPY NON‐RESPONDERS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA USING FDG‐PET QUANTITATIVE PARAMETERS
by: C. Pellegrini, et al.
Published: (2025)

New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model
by: Maria Anele Romeo, et al.
Published: (2024)

14 | PERFORMANCE OF BASELINE AND END‐OF‐TREATMENT FDG‐PET RADIOMICS IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: DATA FROM INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0
by: T. Skrypets, et al.
Published: (2025)

Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
by: Antonio Pinto, et al.
Published: (2024)

One Grammar, Many Labels: Revisiting the Continuum of Myeloid Neoplasms
by: Francesco Tarantini, et al.
Published: (2026)

412 | IMPROVING THE PREDICTIVE VALUE OF END‐OF‐TREATMENT PET/CT IN DIFFUSE LARGE B‐CELL LYMPHOMA
by: A. Bes, et al.
Published: (2025)

515 | PREDICTIVE VALUE OF INTERIM AND END OF TREATMENT PET/CT IN FRONT‐LINE TREATMENT OF PERIPHERAL T‐CELL LYMPHOMA
by: N. Rampi, et al.
Published: (2025)

523 | CORRELATION OF BASELINE PET/CT IMAGING AND MOLECULAR FEATURES WITH CLINICAL OUTCOMES IN A POPULATION‐BASED MCL STUDY
by: A. I. Perez‐Valencia, et al.
Published: (2025)

Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy
by: Nan Wang, et al.
Published: (2024)

390 | END‐OF‐TREATMENT PET/CT COMPLETE REMISSION IS HIGHLY PROGNOSTIC IN NODAL PERIPHERAL T‐CELL LYMPHOMA: AN AUSTRALASIAN‐CANADIAN COLLABORATIVE STUDY
by: C. Abeyakoon, et al.
Published: (2025)

Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert panel
by: Francesca Romana Mauro, et al.
Published: (2024)

739 | ADDRESSING HYPERCALCEMIA IN ADULT T‐CELL LEUKEMIA/LYMPHOMA
by: M. Srinivasan, et al.
Published: (2025)

826 | PET‐CT–ADAPTED TREATMENT FOR EARLY‐STAGE DIFFUSE LARGE B‐CELL LYMPHOMA WITHOUT RISK FACTORS: PRELIMINARY ANALYSIS FROM THE GATLA GROUP
by: A. Cerutti, et al.
Published: (2025)

Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation
by: José Carlos Jaime‐Pérez, et al.
Published: (2024)

Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
by: Evgenia Verrou, et al.
Published: (2024)

Baseline Tumor Burden Assessed With AI‐Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR‐T in Aggressive B‐Cell Lymphoma
by: Eugenio Galli, et al.
Published: (2024)

Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing surveillance in Japan
by: Kenji Ishitsuka, et al.
Published: (2024)

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
by: Beatrice Casadei, et al.
Published: (2024)

Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition
by: João L. Pereira, et al.
Published: (2024)

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma
by: Jiangfang Feng, et al.
Published: (2024)

Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes
by: Xiaohui Wang, et al.
Published: (2024)

Mortality associated to hematological malignancies across pandemic waves in 2020: A nationwide analysis of multiple causes of death in Italy
by: Enrico Grande, et al.
Published: (2024)

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD
by: Carmen Martínez, et al.
Published: (2024)

Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
by: Mohammed Zuber, et al.
Published: (2024)

PET2‐Adapted Therapy in Patients With Advanced‐Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater
by: Antonio Pinto, et al.
Published: (2024)

15 | EARLY PET RESPONSE PREDICTS RISK OF RELAPSE AFTER 2L AXI‐CEL IN LARGE B‐CELL LYMPHOMA
by: A. Kuhnl, et al.
Published: (2025)

6 | FEASIBILITY OF CTDNA AND PET GUIDED THERAPY IN UNTREATED DLBCL. PRELIMINARY RESULTS OF THE SAKK 38/19 PHASE II TRIAL
by: A. Stathis, et al.
Published: (2025)

Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy
by: Hidehiro Itonaga, et al.
Published: (2024)